Edition:
United States

Cogentix Medical Inc (CGNT.OQ)

CGNT.OQ on NASDAQ Stock Exchange Capital Market

3.85USD
4:00pm EDT
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.85
Open
$3.85
Day's High
$3.85
Day's Low
$3.82
Volume
83,449
Avg. Vol
28,999
52-wk High
$3.91
52-wk Low
$1.55

Latest Key Developments (Source: Significant Developments)

Cogentix Medical Enters Definitive Merger Agreement To Be Acquired By Laborie Medical Technologies
Monday, 12 Mar 2018 08:49am EDT 

March 12 (Reuters) - Cogentix Medical Inc ::COGENTIX MEDICAL ENTERS DEFINITIVE MERGER AGREEMENT TO BE ACQUIRED BY LABORIE MEDICAL TECHNOLOGIES FOR A PURCHASE PRICE OF $3.85 PER SHARE IN CASH.COGENTIX MEDICAL INC - DEAL FOR ‍A TOTAL CONSIDERATION OF APPROXIMATELY $239 MILLION​.COGENTIX MEDICAL INC - ‍UPON COMPLETION OF TRANSACTION, COGENTIX MEDICAL WILL BECOME A WHOLLY OWNED SUBSIDIARY OF LABORIE​.COGENTIX MEDICAL INC - COGENTIX MEDICAL WILL NO LONGER ISSUE A PRESS RELEASE ON ITS Q4 AND FULL YEAR 2017 RESULTS.COGENTIX MEDICAL - ‍LABORIE, CAMDEN MERGER SUB WILL COMMENCE TENDER OFFER FOR COGENTIX MEDICAL STOCK FOR $3.85 PER SHARE IN CASH​.COGENTIX MEDICAL - ACCELMED GROWTH PARTNERS LP & LEWIS PELL HAVE ENTERED INTO TENDER & SUPPORT AGREEMENTS IN FAVOR OF LABORIE AND CAMDEN MERGER SUB.COGENTIX MEDICAL - ACCELMED GROWTH PARTNERS LP AND LEWIS PELL COLLECTIVELY BENEFICIALLY OWN SHARES REPRESENTING ABOUT 60% OF CO'S COMMON STOCK.  Full Article

Cogentix Medical Sees FY 2017 Revenue Up About 9 Percent
Tuesday, 6 Feb 2018 07:00am EST 

Cogentix Medical Inc ::COGENTIX MEDICAL ANNOUNCES 17% PRELIMINARY FOURTH QUARTER 2017 YEAR-OVER-YEAR REVENUE GROWTH.SEES FY 2017 REVENUE $56.3 MILLION.SEES FY 2017 REVENUE UP ABOUT 9 PERCENT.COGENTIX MEDICAL-‍PRELIMINARY AND UNAUDITED REVENUE FOR Q4 2017 IS EXPECTED TO BE $15.5 MILLION, OR ABOUT 17% GROWTH COMPARED TO SAME PERIOD IN 2016​.‍UROLOGY REVENUE IS EXPECTED TO BE $49.3 MILLION FOR FULL YEAR OF 2017, REFLECTING GROWTH OF APPROXIMATELY 10% OVER 2016​.FY2017 REVENUE VIEW $55.9 MILLION -- THOMSON REUTERS I/B/E/S.Q4 REVENUE VIEW $15.0 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Cogentix Medical Announces Palmetto GBA Extends Medicare Coverage on Urgent PC
Wednesday, 6 Dec 2017 07:00am EST 

Dec 6 (Reuters) - Cogentix Medical Inc ::COGENTIX MEDICAL - PALMETTO GBA EXTENDED ITS COVERAGE POLICY FOR PERCUTANEOUS TIBIAL NERVE STIMULATION.  Full Article

Cogentix Medical Q3 revenue rose 3 percent
Tuesday, 7 Nov 2017 04:01pm EST 

Nov 7 (Reuters) - Cogentix Medical Inc ::Cogentix Medical reports third quarter results; second highest quarterly revenue in company history.Q3 revenue rose 3 percent to $13.8 million.Cogentix Medical Inc - qtrly earnings per share ‍$0.00​.  Full Article

Cogentix medical Q2 earnings per share $0.01
Tuesday, 1 Aug 2017 04:01pm EDT 

Aug 1 (Reuters) - Cogentix Medical Inc :Cogentix medical reports strong second quarter operating results with 11% urology revenue growth; recently executed business development transactions expected to add approximately 10 points of urology revenue growth in 2018.Q2 earnings per share $0.01.Q2 revenue $14.1 million versus $13 million.  Full Article

Cogentix Medical acquires Genesis Medical
Wednesday, 26 Jul 2017 07:00am EDT 

July 26 (Reuters) - Cogentix Medical Inc ::Cogentix Medical acquires genesis medical; transaction to further increase urology products revenue growth rate.Cogentix Medical - transaction expected to generate incremental revenue to cogentix during second half of 2017 of approximately $0.8 million.Cogentix Medical - transaction expected to generate incremental revenue over $2.0 million of incremental revenue in 2018.Cogentix Medical - under terms of agreement, cogentix has purchased tangible assets of genesis and will pay up to £515,000 for ongoing business.Cogentix Medical says believes that during second half of 2017 co's urology products revenue growth rate will exceed first half's 11 percent.  Full Article

Cogentix enters license with Promepla for endo-urology product line in U.S
Tuesday, 18 Jul 2017 07:25am EDT 

July 18 (Reuters) - Cogentix Medical Inc ::Cogentix Medical Inc - on July 18, co entered into exclusive license with Promepla to launch an endo-urology product line in U.S - SEC filing.Cogentix Medical Inc - management expects Cogentix-branded product line will generate revenue exceeding $2.5 million during 2018.  Full Article

Cogentix Medical signs agreement to launch endo-urology product line in U.S.
Tuesday, 18 Jul 2017 07:00am EDT 

July 18 (Reuters) - Cogentix Medical Inc ::Cogentix Medical signs agreement to launch endo-urology product line in U.S.; launch to further increase urology products growth rate during 2018.Says ‍continue to have $27 million in cash and investments for additional business development opportunities​.Cogentix Medical - transaction is expected to further increase co's strong urology product revenue growth rate, which was about 11 percent during q2 2017.Says ‍expect to complete at least one more transaction in near term​.  Full Article

Cogentix Medical files for mixed shelf of up to $100 mln
Wednesday, 19 Apr 2017 05:15pm EDT 

April 19 (Reuters) - Cogentix Medical Inc ::Files for mixed shelf of up to $100 mln - sec filing.  Full Article

Cogentix says Robert Kill will resign as CEO
Tuesday, 24 May 2016 08:35am EDT 

Cogentix Medical Inc : Robert C. Kill , chairman of board and CEO, will resign as a director and officer of Cogentix . Darin Hammers , current chief operating officer, will be named as interim CEO . Cogentix and its board of directors have agreed to support proposals set forth in definitive proxy statement filed by Lewis C. Pell . Directors Kevin Roche and Ken Paulus will also depart Cogentix pursuant to settlement agreement .Cogentix Medical announces settlement agreement in connection with proxy contest and related litigation and leadership changes; annual meeting to be held may 24, 2016 at 12:00 p.m. Central daylight time.  Full Article

BRIEF-Cogentix Medical Enters Definitive Merger Agreement To Be Acquired By Laborie Medical Technologies

* COGENTIX MEDICAL ENTERS DEFINITIVE MERGER AGREEMENT TO BE ACQUIRED BY LABORIE MEDICAL TECHNOLOGIES FOR A PURCHASE PRICE OF $3.85 PER SHARE IN CASH